Status:
TERMINATED
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Lead Sponsor:
University of Chicago
Conditions:
Preleukemia
Myeloproliferative Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G...
Eligibility Criteria
Inclusion
- Relapsed or refractory acute myelogenous or lymphoid leukemia.
- Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.
- Chronic myelogenous leukemia in accelerated phase or blast-crisis.
- Chronic myelogenous leukemia in second or subsequent chronic phase
- Recurrent or refractory malignant lymphoma or Hodgkin's disease
- Multiple myeloma at high risk for disease recurrence.
- Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
- Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.
Exclusion
- Clinical progression.
- Contra-indications for vaccination.
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00943293
Start Date
May 1 2003
End Date
January 1 2012
Last Update
March 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Uniiversity of Chicago
Chicago, Illinois, United States, 60637